Several reports of isolated instances of cancer after 131I treatment of adults for Graves disease have appeared, but the large United States Public Health Service cooperative study failed to show an increased risk in this group (184-186)
Exogenous h(2)s initiating Nrf2/gpx4/gsh pathway through promoting syvn1-keap1 interaction in diabetic hearts
While exact counts vary by data source, every credible dataset points to the same conclusion: GLP-1 medications have become a major part of womens healthcare in the United States
References Deanfield, John et al., Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial, The Lancet, Published on October 22, 2025, DOI: 10.1016/S0140-6736(25)01375-3 Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT), ClinicalTrials.gov ID NCT03574597,
Individuals with diagnosed growth hormone deficiency (GHD) a recognised endocrine disorder often present with increased visceral adiposity and reduced lean muscle mass
